Abstract
Background: As one of the most common cancers globally, hepatocellular carcinoma (HCC) usually has a poor prognosis. Many HCC patients are usually diagnosed at advanced stages. Therefore, new potential biomarkers for the diagnosis and prognosis of HCC are urgently needed. More and more studies have shown that miR-92a-3p can regulate the occurrence and development of various cancers, but its clinical significance and molecular mechanism in HCC are still elusive. Here, we tried to clarify the regulatory mechanism of miR-92a-3p in HCC.
Methods: In this study, we conducted qRT-PCR and revealed that miR-92a-3p was notably upregulated in HCC cells. MTT, flow cytometry, wound healing, Transwell invasion assays and western blot were conducted to uncover that overexpressed miR-92a-3p could boost the proliferation, migration, invasion and epithelial-mesenchymal transition (EMT) of HCC cells while inhibiting cell apoptosis. In addition, the proteins associated with the PI3K/AKT/mTOR pathway were also detected by western blot.
Results: It was suggested that miR-92a-3p could activate the PI3K/AKT/mTOR signaling pathway.
Conclusion: These results suggest that miR-92a-3p plays a tumor-promoting role in HCC and may be a potential biomarker for the diagnosis and prognosis of HCC.
Keywords: Hepatocellular carcinoma (HCC), miR-92a-3p, PI3K/AKT/mTOR signaling pathway, epithelial-mesenchymal transition (EMT), MTT, MiRNAs.
Current Pharmaceutical Design
Title:MiR-92a-3p Promotes the Malignant Progression of Hepatocellular Carcinoma by Mediating the PI3K/AKT/mTOR Signaling Pathway
Volume: 27 Issue: 29
Author(s): Libing Wang, Mingxin Cui, Fengzhi Qu, Daming Cheng, Jingkun Yu, Zhaoyuan Tang, Ling Cheng, Yanbing Wei, Xiaotang Wu and Xiaogang Liu*
Affiliation:
- Department of Hepatobiliary Surgery, Tangshan Gongren Hospital, Tangshan, 063000,China
Keywords: Hepatocellular carcinoma (HCC), miR-92a-3p, PI3K/AKT/mTOR signaling pathway, epithelial-mesenchymal transition (EMT), MTT, MiRNAs.
Abstract:
Background: As one of the most common cancers globally, hepatocellular carcinoma (HCC) usually has a poor prognosis. Many HCC patients are usually diagnosed at advanced stages. Therefore, new potential biomarkers for the diagnosis and prognosis of HCC are urgently needed. More and more studies have shown that miR-92a-3p can regulate the occurrence and development of various cancers, but its clinical significance and molecular mechanism in HCC are still elusive. Here, we tried to clarify the regulatory mechanism of miR-92a-3p in HCC.
Methods: In this study, we conducted qRT-PCR and revealed that miR-92a-3p was notably upregulated in HCC cells. MTT, flow cytometry, wound healing, Transwell invasion assays and western blot were conducted to uncover that overexpressed miR-92a-3p could boost the proliferation, migration, invasion and epithelial-mesenchymal transition (EMT) of HCC cells while inhibiting cell apoptosis. In addition, the proteins associated with the PI3K/AKT/mTOR pathway were also detected by western blot.
Results: It was suggested that miR-92a-3p could activate the PI3K/AKT/mTOR signaling pathway.
Conclusion: These results suggest that miR-92a-3p plays a tumor-promoting role in HCC and may be a potential biomarker for the diagnosis and prognosis of HCC.
Export Options
About this article
Cite this article as:
Wang Libing , Cui Mingxin , Qu Fengzhi , Cheng Daming , Yu Jingkun, Tang Zhaoyuan , Cheng Ling , Wei Yanbing, Wu Xiaotang and Liu Xiaogang *, MiR-92a-3p Promotes the Malignant Progression of Hepatocellular Carcinoma by Mediating the PI3K/AKT/mTOR Signaling Pathway, Current Pharmaceutical Design 2021; 27 (29) . https://dx.doi.org/10.2174/1381612827666210612054156
DOI https://dx.doi.org/10.2174/1381612827666210612054156 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Follow the ATP: Tumor Energy Production: A Perspective
Anti-Cancer Agents in Medicinal Chemistry Cellular Oxidative/Antioxidant Balance in γ-Irradiated Brain: An Update
Mini-Reviews in Medicinal Chemistry VEGF/VEGFR Pathway Inhibitors as Anti-Angiogenic Agents: Present and Future
Current Cancer Drug Targets Genes that Modulate the Sensitivity for Anti-Microtubule Drug-Mediated Chemotherapy
Current Cancer Drug Targets Antitumor Properties of Natural Compounds and Related Molecules
Recent Patents on Anti-Cancer Drug Discovery The Application of Stimuli-responsive Nanocarriers for Targeted Drug Delivery
Current Topics in Medicinal Chemistry A Network Biology Approach for Assessing the Role of Pathologic Adipose Tissues in Insulin Resistance Using Meta-analysis of Microarray Datasets
Current Genomics Non-Homologous DNA End Joining in Anticancer Therapy
Current Cancer Drug Targets Tumor Protein p63/microRNA Network in Epithelial Cancer Cells
Current Genomics Methods to Assess Tissue-Specific Distribution and Metabolism of Drugs
Current Drug Metabolism Amino Acid Transporter-Targeted Radiotracers for Molecular Imaging in Oncology
Current Medicinal Chemistry Adenoviral Vector Immunity: Its Implications and Circumvention Strategies
Current Gene Therapy Recent Advances and Developments in Treatment Strategies Against Pancreatic Cancer
Current Clinical Pharmacology Endocannabinoids and Their Receptors: Physiology, Pathology and Pharmacology
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) In Vivo Tumor Secretion Probing Via Ultrafiltration and Tissue Chamber:Implication for Anti-Cancer Drugs Targeting Secretome
Recent Patents on Anti-Cancer Drug Discovery Thalidomide: An Overview of its Pharmacological Mechanisms of Action
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Anti-Angiogenesis in Glioblastoma: The Clinical Consequences of Redundancy and Evasion?
Current Angiogenesis (Discontinued) Lipid Nanoparticles to Deliver miRNA in Cancer
Current Pharmaceutical Biotechnology Editorial [Hot Topic: Bacterial Vectors for Gene & Cell Therapy (Guest Editors: Mark Tangney & Cormac G.M. Gahan)]
Current Gene Therapy Anti-VEGF Mediated Immunomodulatory Role of Phytochemicals: Scientific Exposition for Plausible HCC Treatment
Current Drug Targets